CapsoVision, Inc. filed a Form 8-K on August 18, 2026, disclosing that on August 13, 2026, the company entered into an at-the-market equity offering sales agreement with Cantor Fitzgerald & Co. to sell up to $100,000,000 in common stock.

Key Highlights

  • ATM program size: The company may offer and sell shares having an aggregate offering price of up to $100,000,000.
  • Sales agent: Cantor Fitzgerald & Co. will act as "sales agent" or principal under the Sales Agreement.
  • Agreement date: The Controlled Equity Offering Sales Agreement was entered into on August 13, 2026.
  • Registration Statement: A Form S-3 (File No. 333-298315) was filed with the SEC on August 13, 2026, including an at-the-market offering prospectus supplement.
  • Legal opinion: O'Melveny & Myers LLP issued an opinion dated August 13, 2026, relating to the validity of the shares to be issued and sold.
  • Emerging growth company: CapsoVision is classified as an emerging growth company as defined under applicable SEC rules.

CapsoVision's At-the-Market Offering Agreement with Cantor Fitzgerald

According to the filing, CapsoVision, Inc. (NASDAQ:CV) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. on August 13, 2026. Under the agreement, the company may offer and sell, "from time to time at its sole discretion," shares of its common stock, par value $0.001 per share, with an aggregate offering price of up to $100,000,000. The shares may be sold through or to Cantor acting as the company's "sales agent" or principal.

The filing states that CapsoVision simultaneously filed a Registration Statement on Form S-3 (File No. 333-298315) with the SEC on August 13, 2026. That registration statement included an at-the-market offering prospectus supplement. According to the company, any shares offered and sold under the Sales Agreement will be issued pursuant to that Registration Statement and prospectus supplement.

O'Melveny & Myers LLP, described in the filing as "counsel to the Company," issued a legal opinion dated August 13, 2026, addressing the validity of the shares to be issued and sold. That opinion is filed as Exhibit 5.1 to the 8-K, incorporated by reference to Exhibit 5.2 of the Form S-3 registration statement. The 8-K was signed by Kang-Huai (Johnny) Wang, Director, President and Chief Executive Officer, on August 18, 2026.

What Was Disclosed

CapsoVision disclosed the establishment of an at-the-market equity offering program allowing the sale of up to $100,000,000 in common stock through Cantor Fitzgerald & Co., supported by a concurrently filed Form S-3 registration statement and a legal validity opinion from O'Melveny & Myers LLP.